The tweet was deleted by the author.
But we saved everything 🙂.
Emergent Biosolutions, together with PANTHER Health and Africa CDC, has initiated the MpOx Study in Africa (MOSA), with the first patient enrolled in Madagascar. The launch follows a recent declaration of an mpox outbreak in the country.
Institut Pasteur de Madagascar will lead the study to better understand the disease and inform potential response strategies. The partnership aims to accelerate research into mpox transmission and treatment options as the outbreak evolves. Details regarding the study's timeline and scope are still being clarified.
Emergent Biosolutions has previously focused on public health interventions, such as evaluating the safety and pharmacokinetics of multi-dose intranasal naloxone for opioid overdose response. The current mpox study expands the company's involvement in infectious disease research. Updates on the study's progress are expected as more patients are enrolled.